ACA
REGN icon

Ascension Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Ascension Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-344
Closed -$208K – 39
2021
Q3 		$208K Buy
+344
New +$214K 0.14% 32

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Ascension Capital Advisors's REGN Position: Q4 2021 in Review

Ascension Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2021, closing a stake of 344 shares — an estimated $208K sold.

Ascension Capital Advisors first reported a position in REGN in Q3 2021 and held it in 1 quarter. The position peaked at $208K in Q3 2021. 1,080 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

  • Ascension Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Ascension Capital Advisors sold 344 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $208K.
  • Ascension Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Ascension Capital Advisors's Regeneron Pharmaceuticals position peaked at $208K in Q3 2021.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on Ascension Capital Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.